South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Insitro is raising $143,210,951.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Daphne Koller played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. We’re embarking on a new approach to drug development one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry.

To learn more about Insitro, visit http://insitro.com/

Contact:
Daphne Koller, Chief Executive Officer
650-730-7074
https://www.linkedin.com/in/daphne-koller-4053a820/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved